2.

Clinical data of enrolled patients

Number	Sex	Age (year)	Location	Pathological type	Primary location	Staging	Chemotherapy regimen	Mechanical index	Times
1Irinotecan 165 mg/m2 intravenous guttae (ivgtt) d 1, oxaliplatin 85 mg/m2 ivgtt d 1, fluorouracil 400 mg/m2 ivgtt d 1, 2,400 mg/m2 continuous intravenous infusion (civ) 46 h, Q14d; 2irinotecan 165 mg/m2 ivgtt d 1, fluorouracil 400 mg/m2 ivgtt d 1, 2,400 mg/m2 civ 46 h, cetuximab 400 mg/m2 ivgtt d 1, 250 mg/m2 per week, Q14d; 3gemcitabine 1,000 mg ivgtt d 1, d 8, oxaliplatin 130 mg/m2 ivgtt d 1, Q21d; 4irinotecan 180 mg/m2 ivgtt d 1, cetuximab 400 mg/m2 d 1, 250 mg/m2 per week, Q14d; 5irinotecan 180 mg/m2 ivgtt d 1, fluorouracil 400 mg/m2 ivgtt d 1, 2,400 mg/m2 civ 46 h, bevacizumab 5 mg/kg d 1, Q14d; 6irinotecan 130 mg/m2 ivgtt d 1, Q21d; 7gemcitabine 1 g/m2 ivgtt d 1, d 8, S-1 60 mg po bid d 1−14, Q21d;8oxaliplatin 130 mg/m2 ivgtt d 1, capecitabine 1,000 mg/m2 po bid, d 1−14, Q21d.
A1	Male	51	Liver	Poorly differentiated adenocarcinoma	Pancreas	T4N1M1	FOlFOXIRI1	0.4	9
A2	Male	54	Liver	Moderately differentiated adenocarcinoma	Colon	T4N1M1	FOLFIRI + Cetuximab2	0.4	3
A3	Male	55	Liver	Moderately differentiated adenocarcinoma	Gallbladder	T4N1M1	Gemox3	0.4	2
B1	Male	63	Liver	Moderately differentiated adenocarcinoma	Colon	T4N1M1	FOLFIRI + Cetuximab	0.6	6
B2	Male	61	Liver	Moderately differentiated adenocarcinoma	Colon	T4N1M1	Irinotecan + Cetuximab4	0.6	3
B3	Female	64	Liver	Moderately differentiated adenocarcinoma	Colon	T4N1M1	FOLFIRI + Bevacizumab5	0.6	9
C1	Male	62	Liver	Neuroendocrine carcinoma	Colon	T4N1M1	Irinotecan6	0.8	2
C2	Female	58	Pancreas	Mucous moderately differentiated adenocarcinoma	Pancreas	T4N1M1	Gemcitabine + S-17	0.8	2
C3	Male	59	Liver	Moderately differentiated adenocarcinoma	Colon	T3N1M1	FOLFIRI + Bevacizumab	0.8	6
D1	Male	65	Liver	Moderately differentiated adenocarcinoma	Colon	T3N1M1	FOLFIRI + Cetuximab	1.0	6
D2	Male	64	Liver	Moderately differentiated adenocarcinoma	Colon	T4N1M1	XELOX8	1.0	2
D3	Male	51	Liver	Moderately differentiated adenocarcinoma	Colon	T4N1M1	FOLFOXIRI	1.0	6